Myodegeneration

A special issue of Muscles (ISSN 2813-0413).

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 448

Special Issue Editors


E-Mail Website
Guest Editor
Institute of Neuropathology, University Hospital Zurich, Zurich, Switzerland
Interests: neurodegeneration; neuropathology; neurodegenerative diseases; prion diseases; prion protein; molecular neurobiology; degenerative muscular disease; inclusion body myositis (IBM)

E-Mail Website
Guest Editor
1. Institute of Pathology, Cantonal Hospital, Luzern, Switzerland
2. MEDICA Medical Laboratories, Zurich, Switzerland
Interests: brain tumors; infectious diseases; inflammatory muscle diseases

Special Issue Information

Dear Colleagues,

Myodegeneration is a controversial and poorly defined designation that rarely appears in textbooks and publications. Mainly introduced in the context of inclusion body myositis (IBM), the term refers to a pathogenesis or pathological alteration in skeletal muscle, similar to that described for neurodegeneration in the central nervous system. Key to the concept of “classical” neurodegeneration is the progressive loss of neurons, which represents a significant difference between these two tissues. Muscle fibers, unlike neurons, are capable of regeneration. Myodegeneration is therefore best understood in the earlier investigations of V. Askanas and W.K. Engel, who compared the pathological findings in IBM with those of Alzheimer disease. In this sense, myodegeneration could be regarded as the accumulation of pathological protein aggregates. This broader interpretation applies to IBM and hereditary inclusion body myopathies. Other myopathies accompanied by (rimmed) vacuoles, such as myofibrillar myopathies and selected distal myopathies (e.g., Welander myopathy), also fulfill this criterion. This Special Issue aims to summarize the cardinal aspects of myodegeneration, including a systematic comparison of the diseases with protein aggregates in skeletal muscle. An additional aim is to analyze and better define the following terms.

  • “Myodegeneration”
  • Myofiber degeneration
  • Inclusion body myositis (IBM)
  • Hereditary inclusion body myopathies
  • Rimmed vacuoles
  • Protein aggregation in skeletal muscle

Dr. Regina R. Reimann
Prof. Dr. Elisabeth Rushing
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Muscles is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop